An Entity of Type: Public company, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Phio Pharmaceuticals Inc. is a US biotechnology company focused on the field of siRNA. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phios Pharmaceuticals in 2018. The company is using its siRNA platform to develop a pipeline of dermatology and ophthalmology therapeutics. The company has developed self-delivering RNAi compounds for the treatment of dermal and retinal scarring and is also working on a proprietary topical formulation of diphenylcyclopropenone for the treatment of warts, alopecia areata and cutaneous metastases of melanoma.

Property Value
dbo:abstract
  • Phio Pharmaceuticals Inc. is a US biotechnology company focused on the field of siRNA. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phios Pharmaceuticals in 2018. The company is using its siRNA platform to develop a pipeline of dermatology and ophthalmology therapeutics. The company has developed self-delivering RNAi compounds for the treatment of dermal and retinal scarring and is also working on a proprietary topical formulation of diphenylcyclopropenone for the treatment of warts, alopecia areata and cutaneous metastases of melanoma. (en)
dbo:foundingYear
  • 2011-01-01 (xsd:gYear)
dbo:industry
dbo:keyPerson
dbo:location
dbo:type
dbo:wikiPageID
  • 35289132 (xsd:integer)
dbo:wikiPageLength
  • 9299 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1082536316 (xsd:integer)
dbo:wikiPageWikiLink
dbp:foundation
  • 2011 (xsd:integer)
dbp:industry
dbp:keyPeople
  • Geert Cauwenbergh (en)
  • Robert Bitterman (en)
dbp:location
dbp:name
  • Phio Pharmaceuticals (en)
dbp:tradedAs
  • NASDAQ:PHIO (en)
dbp:type
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Phio Pharmaceuticals Inc. is a US biotechnology company focused on the field of siRNA. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phios Pharmaceuticals in 2018. The company is using its siRNA platform to develop a pipeline of dermatology and ophthalmology therapeutics. The company has developed self-delivering RNAi compounds for the treatment of dermal and retinal scarring and is also working on a proprietary topical formulation of diphenylcyclopropenone for the treatment of warts, alopecia areata and cutaneous metastases of melanoma. (en)
rdfs:label
  • Phio Pharmaceuticals (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
foaf:name
  • Phio Pharmaceuticals (en)
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License